Meeting Report
Collaborative Management of Patients With Estrogen Receptor–Positive Breast Cancer
Presented by Lee S. Schwartzberg, MD, FACP, and Heather R. Greene, MSN, FNP, AOCNP®
West Cancer Center, Memphis, Tennessee
Presenters’ disclosures of potential conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2017;8:250–254 |
https://doi.org/10.6004/jadpro.2017.8.3.6 |
© 2017 Harborside Press®
ABSTRACT
Cyclin-dependent kinase (CDK) inhibitors represent a new form of cytotoxic chemotherapy. Advanced practitioners can read this article to find out about the science behind CDK inhibition, when CDKs are indicated, how to monitor for and manage side effects, as well as when and how to dose adjust.
For access to the full length article, please
sign in.
